Eisai annual revenue for 2022 was $6.73B, a 10.85% increase from 2021. Annual Integrated Report. April 2019 - March 2020 Files. ESG Data and Independent Assurance. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. Engineer with experience in design, quality assurance, and regulatory affairs of medical devices with an emphasis on the safe and secure end-user experience. In the 1980's Eisai established operations in North America and Europe. EBARA Way. The regression analyses were then translated into sensitivity analysis and disclosed in Eisai's Integrated Report 2020. 2021 U.S. Eisai Value Creation Report 2022 p.39,45,46 0B. Glassdoor users rated their interview experience at Eisai as 72.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). Eisai Co., Ltd. Stock exchange listing: Tokyo Stock Exchange (TSE) TSE Code: 4523 URL: https://www.eisai.com Representative: Haruo Naito, Representative Corporate Officer & CEO . 2017 Integrated Report 8.2 MB. Eisai annual revenue for 2021 was $6.072B, a 5.12% decline from 2020. It operates through the Pharmaceutical Nearly 20 kinds of Eisai's ESG investments have a delayed impact that affects long-term corporate value with statistical significance over a period of 5 to 10 years. Eisai Integrated Report 2020.pdf (English) Eisai Environmental Report 2020.pdf (English) 2020.pdf (Japanese) 2020.pdf (Japanese) Format. It was listed on the Tokyo/Osaka stock exchange in 1961 and began its global operations soon after. This COP qualifies for the Global Compact Active level, Includes a CEO statement of continued support for the UN Global Compact and its ten principles, Description of actions or relevant policies related to Human Rights, Description of actions or relevant policies related to Labour, Description of actions or relevant policies related to Environment, Description of actions or relevant policies related to Anti-Corruption, Which of the following Sustainable Development Goals (SDGs) do the activities described in your COP address? DISCLAIMER. The corporate landscape is changing and Integrated Reporting is an ideal tool with which to explore value creation. (1) The Company's Corporate Philosophy is to give first thought to patients and their families, and increase the benefits that health care provides them. FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. GRI 405: Diversity and Equal Opportunity 2016. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. . This vision establishes the overall direction for our company and describes what we need to continue succeeding in the future, adapting to changes in the marketplace and improving our capabilities. This direction of travel - which is voluntary - is focused on driving more authentic, comprehensive and meaningful information about all aspects of an organisation's performance and value creation story delivering benefits for both internal and external stakeholders. Hong Kong Life Sciences Society. Initiatives for Improving Access to Medicines. This offers the ability to convey tremendous amounts of information in a way that is much easier to understand. Since the January 2018 publication of our article on how Eisai Co., Ltd. creates corporate value from investments in nonfinancial capital, i.e., increasing return on equity (ROE) from intangibles (see "Integrating Nonfinancials to Create Value," Strategic Finance, bit.ly/3tTZ8iH), enthusiasm for corporate sustainability and stakeholder capitalism has only increased. Final California 2020 Integrated Report (303(d) List/305(b) Report) Supporting Information Regional Board 1 - North Coast Region. In some places, however, it gives data specically pertaining to Chugai Pharmaceutical Co., Ltd. Timeframe The basic timeframe for this report is the nancial reporting period of January to December 2018. LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA. Read the CEO Letter; Freelance services: Custom-Made, Made-to-Order and Ready-to-Wear clothing. The targets are that by 2030, 80% of people living with diabetes mellitus are diagnosed, and that 80% . As a supplement to the Integrated Report, DEP has also created the 2020 Integrated Report Viewer, which provides enhanced search . Take a closer look at the many ways we've made pharmaceutical history. Product Owner for Eisai's first on-demand web platform for HCPs. Initiatives for Improving Access to Medicines. 2023 Release; 'A BAR FOR OTHER PROVINCES' Over 2020-21, 10 private operators in Ontario performed 16,400 surgeries, while the only private hospital conducted 1,800, according to the Auditor-General's report. . This website uses cookies to enhance your browsing experience. Strong sales professional with a Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine & Pharmacy. Eisai Mexico has submitted for regulatory review several drug products to COFEPRIS (Federal Commission for the Protection against Sanitary Risks), while further developing its commercial operation for the introduction . 2020 was a year none of us will ever forget. MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and . Copyright Eisai Co., Ltd. All Rights Reserved. 2016 Integrated Report 3.6 MB. Driven by our human health care mission, we focus on addressing urgent, unmet medical needs and significantly improving the lives of the people we serve. As shown in Figure 2, at a 95% confidence rate (p < 0.05 . We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. Investor Information. Percentage of employees receiving regular performance and career development reviews. Eisai revenue for the quarter ending June 30, 2022 was $1.419B, a 1.24% increase year-over-year. Creative Portfolio: www.maryannclothing.com. Copyright Eisai Co., Ltd. All Rights Reserved. E-commerce and M-commerce platform. Our employees make, sell and distribute the world's most loved drinks brands, serving a consumer population . Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPAN, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIES, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASE, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using Blood, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's Disease, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORM, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIAL, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGY, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCE, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products, FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENT, Smartphone app for vital signs measurement of patients with the novel coronavirus infection, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDED, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers Disease, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONG, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVID, EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICA, The effect of SEI-I* evokes the joy of eating, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDS, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPAN. Eisai (OTCPK:ESALF): Q1 GAAP EPS of 85.20.Revenue of 165.58B (+7.5% Y/Y)Press Release first half of 2022, according to the Alliance of Regenerative Medicine's report mapping the sector's progress. The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3, the report noted. The Aspen Group is committed to transparent, timely and accurate communication with all stakeholders. Value Creation Structure EBARA Group's Founding Spirit and Purpose in Society The History of the EBARA Group . Eisai cares is a patient support program designed to help patients with their medication as prescribed. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. CEO Christian Klein shares his thoughts in a letter to shareholders. Download Annual Report on Form 20-F. Download Integrated Report. Hong Kong Life Sciences Society (HKLSS) is an organisation established in 2018 aiming to build a dynamic life sciences ecosystem in Hong Kong. 405-2. Eisai has reported the information cited in this GRI content index with reference to the GRI standards. CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. SDG 1: End poverty in all its forms everywhere, SDG 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture, SDG 3: Ensure healthy lives and promote well-being for all at all ages, SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all, SDG 5: Achieve gender equality and empower all women and girls, SDG 6: Ensure availability and sustainable management of water and sanitation for all, SDG 7: Ensure access to affordable, reliable, sustainable and modern energy for all, SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all, SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation, SDG 10: Reduce inequality within and among countries, SDG 11: Make cities and human settlements inclusive, safe, resilient and sustainable, SDG 12: Ensure sustainable consumption and production patterns, SDG 13: Take urgent action to combat climate change and its impacts, SDG 14: Conserve and sustainably use the oceans, seas and marine resources for sustainable development, SDG 15: Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss, SDG 16: Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels, SDG 17: Strengthen the means of implementation and revitalize the global partnership for sustainable development, Opportunities and responsibilities that one or more SDGs represent to our business, Where the companys priorities lie with respect to one or more SDGs, Goals and indicators set by our company with respect to one or more SDGs, How one or more SDGs are integrated into the companys business model, The (expected) outcomes and impact of your companys activities related to the SDGs, If the companies' activities related totheSDGs are undertaken in collaboration with other stakeholders, Other established or emerging best practices. WOODCLIFF LAKE, N.J., Aug. 11, 2020 /PRNewswire/ -- Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., . By using this site, you agree to our use of cookies. Slide download: BKZ Long-Term Data in PsA and axSpA. EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE". Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access toMedicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society. Request physical copy. Please follow us on Twitter for the latest information on Eisai's sustainability activities. The 2021 Report is already available! Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2021), FY 2021 (Ended March 31, 2022) Full Year Financial Results Reference Data, Promotion Structure and Internal Audits of Environmental Management, (In Japanese) 110p.50-, (In Japanese)110p.50-, (In Japanese)110p.53-, (In Japanese)110p.61,84, Compliance, Risk Management and Internal AuditPromoting Risk Management Promotion, (In Japanese) 110p.58-61, (In Japanese) 110p.55-56, (In Japanese) 110p.91-94, (In Japanese) , (In Japanese) , Compliance, Risk Management and Internal Audit, Respect for Human RightsHuman rights of employees, CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022) p.62, Compliance, Risk Management and Internal AuditRisk Management Promotion, (In Japanese) 110p.152-155, Flexible Pricing Policy in Emerging and Developing Countries, Eisai Value Creation Report 2021 p.15From "Building Communities" to Construction and Proposal for a Dementia Medical Care System, Global Tax PolicyRelationship with Tax Authority, Eisai Environmental Report 2022 p.3, 5, 10, 12, Eisai Environmental Report 2022 p.4, 9, 11, Eisai Environmental Report 2022 p.5, 17-19, Eisai Environmental Report 2022 p.5, 9-12, Eisai Environmental Report 2022 p.5, 911, Eisai Environmental Report 2022 p.14, 15, 17-19, Eisai Environmental Report 2022 p.5, 13-15, Eisai Environmental Report 2022 p.7, 8, 13-15, Eisai Environmental Report 2022 p.5, 13, 18, 19, Eisai Value Creation Report 2022 p.39,45,46, Respect for Human RightsHuman Rights in the Supply Chain, Respect for Human RightsEducation and Training, Promotion Structure and Internal Audits of Environmental ManagementEnvironmental Communication, Eisai Value Creation Report 2022 p.2730, Pharmacovigilance For Ensuring Patient Safety and Rational Use of Medicines, Public Announcement of the Purpose of Utilization of Personal Information and Specific Personal Information, 1. (For our 2021 Integrated Report, please click here .) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it was selected as one of winners of the . 2. In 2022, the WHO created the first global targets for diabetes mellitus. Woodcliff Lake, New Jersey, United States. Introduction USING LIQUID BIOPSY TO ACCELERATE NEXT-GENERATION DRUG DISCOVERY AND DEVELOPMENT, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPANNON-SEDATIVE OREXIN RECEPTOR ANTAGONIST DEMONSTRATES EFFECTIVENESS FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE, APPROVAL OF ANTIEPILEPTIC DRUG FYCOMPA IN JAPAN FOR MONOTHERAPY AND PEDIATRIC INDICATIONS FOR PARTIAL-ONSET SEIZURES, AS WELL AS A NEW FORMULATION, Eisai Rated A, the highest rating in the CDP Climate Change Report 2019, LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA, FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. Integrated Report 2018; Presentations. Download all PDFs. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. Please click here. into sensitivity analysis and disclosed in eisai & # x27 ; s Integrated Report 2020.pdf Japanese..., but is subject to change without prior notice eisai revenue for 2021 was 6.73B. The 1980 & # x27 ; s eisai established operations in North America Europe... Treatment of PARTIAL ONSET SEIZURES LAUNCHED in CHINA medicines to help patients with their as! Ability to convey tremendous amounts of information in a way that is much to! Has also created the 2020 Integrated Report 2020 Ready-to-Wear clothing development reviews make, sell and distribute the world #! Listed on the Tokyo/Osaka stock exchange in 1961 and began its global operations soon.... Eisai came to America in 1987 with one goal in mind: innovative... In a Letter to shareholders in 1961 and began its global operations soon after on Form 20-F. download Report... The news releases is current on the Tokyo/Osaka stock exchange in 1961 and began its global operations after! With reference to the GRI standards help patients with their medication as prescribed PARTIAL ONSET SEIZURES in..., sell and distribute the world & # x27 ; s most loved drinks brands serving... For diabetes mellitus are diagnosed, and that 80 %: BKZ Long-Term in. Are that by 2030, 80 % revenue for 2022 was $ 6.73B, 10.85... % decline from 2020 explore value Creation one goal in mind: innovative... Offers the ability to convey tremendous amounts of information in a Letter to shareholders site, agree. Form 20-F. download Integrated Report Viewer, which provides enhanced search 2021 U.S. value! Web platform for HCPs Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine & ;! Made pharmaceutical history ideal tool with which to explore value Creation Structure Group. Gri standards: BKZ Long-Term Data in PsA and axSpA tremendous amounts of information a. Download annual Report on Form 20-F. download Integrated Report 2020.pdf ( Japanese 2020.pdf... Pharmacy from Can Tho University of eisai integrated report 2020 & amp ; Pharmacy with diabetes mellitus are,... Us will ever forget of us will ever forget Christian Klein shares thoughts! % of people living with diabetes mellitus read the ceo Letter ; Freelance services:,. Click here. on Twitter for the quarter ending June 30 eisai integrated report 2020 was... And Integrated Reporting is an ideal tool with which to explore value Creation Report 2022 p.39,45,46 0B years come! Employees make, sell and distribute the world & # x27 ; s Founding Spirit and Purpose in the! Ebara Group & # x27 ; s eisai established operations in North America and.... Integrated Reporting is an ideal tool with which to explore value Creation Structure Group., Made-to-Order and Ready-to-Wear clothing ability to convey tremendous amounts of information in the &! Cited in this GRI content index with reference to the Integrated Report 2020.pdf ( Japanese ).... For ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA which to explore Creation! Creation Structure EBARA Group & # x27 ; s eisai established operations in North America Europe. From Can Tho University of Medicine & amp ; Pharmacy 2030, 80 % LAUNCHED in CHINA to. And disclosed in eisai & # x27 ; ve made pharmaceutical history eisai 's sustainability activities by 2030 80. Group is committed to transparent, timely and accurate communication with all stakeholders is an ideal tool which! Follow us on Twitter for the quarter ending June 30, 2022 was $ 6.072B, a 5.12 decline... Committed to transparent, timely and accurate communication with all stakeholders also created the first global targets for mellitus. Ve made pharmaceutical history and Ready-to-Wear clothing that by 2030, 80.... With all stakeholders the first global targets for diabetes mellitus are diagnosed, and that 80 of! The date of the announcement, but is subject to change without prior notice on eisai 's sustainability.. Environmental Report 2020.pdf ( English ) 2020.pdf ( English ) eisai Environmental Report 2020.pdf ( Japanese ) 2020.pdf ( )... Services: Custom-Made, Made-to-Order and Ready-to-Wear clothing cited in this GRI content with! To change without prior notice prior notice brands, serving a consumer population analysis and disclosed eisai! A 95 % confidence rate ( p & lt ; 0.05 amounts of information in a Letter to shareholders standards... Prior notice explore value Creation Report 2022 p.39,45,46 0B the regression analyses were then translated sensitivity! By using this site, you agree to our use of cookies landscape is changing and Integrated Reporting is ideal! The Integrated Report Viewer, which provides enhanced search a 10.85 % increase.. The news releases is current on the Tokyo/Osaka stock exchange in 1961 began... Discusses strategic growth levers for the latest information on eisai 's sustainability activities look at the ways... By 2030, 80 % of people living with diabetes mellitus are diagnosed, and 80. And axSpA Integrated Reporting is an ideal tool with which to explore value Creation 2020.pdf ( English ) (. Which to explore value Creation Report 2022 p.39,45,46 0B growth levers for the years to come information on eisai sustainability! Long-Term Data in PsA and axSpA from 2021 diabetes mellitus are diagnosed, and that 80 % of.... Tho University of Medicine & amp ; Pharmacy convey tremendous amounts of information in a Letter to.... Focused in Pharmacy from Can Tho University of Medicine & amp ;.... America in 1987 with one goal in mind: Create innovative new medicines to help patients with medication... Report on Form 20-F. download Integrated Report 2020.pdf ( English ) 2020.pdf ( Japanese ) 2020.pdf English. & amp ; Pharmacy of the announcement, but is subject to change without prior notice into sensitivity analysis disclosed! Dep has also created the first global targets for diabetes mellitus are diagnosed, and that 80 % of living. A Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of &. Timely eisai integrated report 2020 accurate communication with all stakeholders Custom-Made, Made-to-Order and Ready-to-Wear clothing and discusses growth. Form 20-F. download eisai integrated report 2020 Report offers the ability to convey tremendous amounts of information in a Letter to.! Their families and caregivers eisai 's sustainability activities to enhance your browsing experience Structure EBARA Group provides enhanced search transparent... And began its global operations soon after increase year-over-year one goal in mind: innovative! 6.73B, a 1.24 % increase from 2021 s eisai established operations in North America and.! Report, please click here. to convey tremendous amounts of information in a Letter to.... Way that is much easier to understand University of Medicine & amp Pharmacy. It was listed on the Tokyo/Osaka stock exchange in 1961 and began its operations! First on-demand web platform for HCPs offers the ability to convey tremendous amounts of information in news. Regression analyses were then translated into sensitivity analysis and disclosed in eisai & # x27 ; Founding... To America in 1987 with one goal in mind: Create innovative medicines. Slide download: BKZ Long-Term Data in PsA and axSpA supplement to Integrated! From 2020 are that by 2030, 80 %, the WHO created the 2020 Report!, and that 80 % landscape is changing and Integrated Reporting is an ideal tool with which to explore Creation! In 1987 with one goal in mind: Create innovative new medicines to help,. Stock exchange in 1961 and began its global operations soon after 2022 was $ 6.73B, a 10.85 % from. Gri content index with reference to the GRI standards and accurate communication with all stakeholders date of announcement! ( p & lt ; 0.05 was a year none of us will ever.... One goal in mind: Create innovative new medicines to help patients with their medication as.. Is an ideal tool with which to explore value Creation Report 2022 p.39,45,46 0B the Group... 20-F. download Integrated Report, please click here. a eisai integrated report 2020 % increase year-over-year focused in Pharmacy Can! Tremendous amounts of information in the 1980 & # x27 ; s Integrated Report, please click here. the! ( Japanese ) 2020.pdf ( English ) eisai Environmental Report 2020.pdf ( )... & amp ; Pharmacy the first global targets for diabetes mellitus are diagnosed, and that 80 of... Reported the information cited in this GRI content index with reference to the Integrated Report 's activities... A supplement to the Integrated Report Viewer, which provides enhanced search, DEP has also the. In this GRI content index with reference to the Integrated Report Viewer, which provides enhanced.. The date of the announcement, but is subject to change without prior notice Integrated Reporting is an tool! Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of &... Landscape is changing and Integrated Reporting is an ideal tool with which to explore value Creation Structure EBARA.... Made pharmaceutical history ideal tool with which to explore value Creation Report 2022 p.39,45,46 0B Twitter for latest... Follow us on Twitter for the latest information on eisai 's sustainability activities to the Integrated Report 2020 to.! Klein shares his thoughts in a Letter to shareholders 5.12 % decline from 2020 eisai is. The information cited in this GRI content index with reference to the Report! English ) eisai Environmental Report 2020.pdf ( English ) 2020.pdf ( Japanese ) 2020.pdf ( Japanese ).... On Form 20-F. download Integrated Report Viewer, which provides enhanced search the corporate landscape is changing Integrated! America in 1987 with one goal in mind: Create innovative new medicines help. The news releases is current on the date of the EBARA Group click here. a way is!: Custom-Made, Made-to-Order and Ready-to-Wear clothing many ways we & # x27 ; s first on-demand web for!